A Paradigm Shift in Disease-Modifying Therapy Treatment Rates for Progressive Forms of Multiple Sclerosis Largely Dependent Upon Genentech’s Ocrevus Prescribing Patterns
The next opportunity for expansion of the treated patient pool for progressive forms of multiple sclerosis relies on potential launches of Novartis’ siponimod, MedDay Pharmaceuticals’ MD-1003, and AB Science’s masitinib, or label expansions of Genzyme’s Lemtrada or EMD Serono’s Mavenclad, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., June […]
US Dermatologists Report Significant Growth of Next-Generation Psoriasis Biologics—Novartis’ Cosentyx, Eli Lilly’s Taltz, and Janssen’s Tremfya
Growth of the IL-17 inhibitors and Tremfya has been at the expense of the established TNF inhibitors and Janssen’s own Stelara. Download Report Overview EXTON, Pa., June 12, 2018 /PRNewswire/ — Spherix Global Insights’ second quarter update of RealTime Dynamix™: Psoriasis (US) reveals significant changes afoot in the current psoriasis biologic landscape. Year-over-year analysis indicates […]
Ocrevus Proves Mettle in Real-World PPMS – Adverse events from ongoing study in line with major trial results
From: MedPage Today By: Salynn Boyles, Contributing Writer, MedPAge Today NASHVILLE — Ocrelizumab (Ocrevus), the first and only FDA-approved disease-modifying therapy (DMT) to treat primary progressive multiple sclerosis (PPMS), has lived up to its hype, according to the CEO of the Consortium of Multiple Sclerosis Centers (CMSC). “Ocrelizumab has really changed the landscape for patients […]
Biosimilars in Nephrology: Pfizer’s Retacrit Gets FDA Clearance and Prepares to Challenge Amgen’s Anemia Franchise Head On
The latest quarterly anemia report from Spherix Global Insights indicates a receptive audience for biosimilar erythropoietin stimulating agents (ESAs), but also a pre-dialysis market looking for ESA-alternatives to anemia management. Download Report Overview EXTON, Pa., May 31, 2018 /PRNewswire/ — Following the receipt of two Complete Response Letters from the FDA related to manufacturing issues, […]
TNF Cycling in Psoriatic Arthritis Declines for the Second Year in a Row as Newly Approved Agents Such as Pfizer’s Xeljanz and Eli Lilly’s Taltz Claim Their Share of the Switching Population
According to Spherix Global Insights, data from over 1,000 psoriatic arthritis patients who recently switched therapies reveals that clinical factors, such as joint and skin efficacy, often drive the decision to switch, while non-clinical factors often influence the choice of the new brand. Download Report Overview EXTON, Pa., May 30, 2018 /PRNewswire/ — With four […]
Warning to Eli Lilly’s Olumiant (baricitinib): Entrenched First-to-Market Rheumatoid Arthritis Products are Tough to Unseat
After a year on the market, Sanofi/Regeneron’s Kevzara has had little success overthrowing Roche/Genentech’s Actemra as the go-to IL-6 inhibitor for treating rheumatoid arthritis (RA) Download Report Overview EXTON, Pa., May 10, 2018 /PRNewswire/ — According to Spherix Global Insights’ second quarter update of RealTime Dynamix™: Rheumatoid Arthritis (US), at just under one-year post-launch, less […]
The US Renal Anemia Market Sees Some Shifting As Mircera Use Expands Beyond Fresenius Medical Care Clinics and Auryxia Makes its Debut with a New Iron Deficiency Anemia Indication in the Pre-Dialysis Setting
According to a recent report published by Spherix Global Insights, about one-third of the surveyed nephrologists (n=202) report the unmet need for new treatments for renal anemia is high. However, other many areas within nephrology, such as diabetic nephropathy and acute kidney injury, are considered a higher priority for new therapeutic options. Download Report Overview […]
Sanofi/Regeneron’s Dupixent, the Darling of Atopic Dermatitis
According to the latest update from Spherix Global Insights, dermatologists are highly satisfied with Dupixent, but a robust pipeline promises to bring competition. How much of a competitive advantage will its first-to-market status be? Download Report Overview EXTON, Pa., May 3, 2018 /PRNewswire/ — Since the March 2017 launch, growth and adoption of Dupixent has […]
Recent Chart Audit of Multiple Sclerosis Patients Recently Switched to a New Disease-Modifying Therapy Shines Spotlight on Gains by Genentech’s Ocrevus in the Secondary Progressive and Primary Progressive Patient Segments
The oral disease-modifying therapy class remains the switch share leader although a shift into the first-line position and recent branded and generic launches has consistently chipped away at class share year-over-year, according to a new independent audit from Spherix Global Insights Download Report Overview EXTON, Pa., April 25, 2018 /PRNewswire/ — With the highest self-reported […]
Pfizer’s Xeljanz Barrels into Psoriatic Arthritis, Leaving Lilly’s Recently Launched Taltz in its Wake, According to a Recently Published Study from Spherix Global Insights
Janssen’s Simponi Aria and BMS’ Orencia seem to be settling into their respective niches, but neither brand is anticipated to bring much disruption to the PsA market Download Report Overview EXTON, Pa., April 9, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by Spherix Global Insights with 101 US rheumatologists reveals […]
